1. Ranga Rao, A., Phang, S.M., Sarada, R., Ravishankar, G.A. Astaxanthin: Sources, extraction, stability, biological activities and its commercial applications – A review. Mar. Drugs. 2014, 12, 128–152. 2.
  2. Pashkow, F.J., Watumull, D.G., Campbell, C.L. Astaxanthin: A novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol. 2008 May 22;101(10A):58D-68D.
  3. Park JS, Chyun JH, Kim YK, Line LL, Chew BP. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutr Metab (Lond). 2010, 7:18.
  4. Nishida, Y., Yamashita, E., Miki, W. Quenching activities of common hydrophilic and lipophilic antioxidants against singlet oxygen using chemiluminescence detection system. Carotenoid Science, 2007, 11, 16–20.
  5. Miki, W. Biological functions and activities of animal carotenoids. Pure Appl. Chem. 1(63), 1991, 141–146.
  6. Naguib, Y.M.A. Antioxidant activities of astaxanthin and related carotenoid. J. Agric. Food Chem. 48, 2000, 1150–1154.
  7. Lee, S., et al. (2003). “Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing IkB Kinase-dependent NFR-kB activation.” Molecules and Cells. 16(1):97-105.
  8. Choi, SK., et al. (2008). “Effects of astaxanthin on the production of NO and the expression of COX-2 and iNOS in LPS-stimulated BV2 microglial cells.” Journal of Microbiology and Biotechnology. 18(12):1990-1996.
  9. Sakai, S., et al. (2009). “Inhibitory effect of carotenoids on the degranulation of mast cells via suppression of antigen-induced aggregation of high affinity IgE receptors.” The Journal of Biological Chemistry. 284(41):28172-28179.
  10. Mason, P., et al. (2006). “Refecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity,” Journal of Cardiovascular Pharmacology. 47(1): S7–S14.
  11. Kidd, P. (2011). “Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential.” Alternative Medicine Review. 16(4):355-364.
  12. Nagaki Y. et al., Effect of astaxanthin on accommodation and asthenopia. Folia Ophthalomogica Japonica. 2010;3(5):461-68. 6.
  13. Ekpe, L., Inaku, K., Ekpe, V. Antioxidant effects of astaxanthin in various diseases – A review. J Mol Pathophysiol, 2018, 7(1): 1-6.
  14. Shimidzu, N., Goto, M., Miki, W. (1996). “Carotenoids as singlet oxygen quenchers in marine organisms.” Fisheries Science. 62(1): 134-137.
  15. Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1679-85.
  16. J Pharm Pharmacol. 2008 Oct;60(10):1365-74.
  17. Ophthalmology 2008 Feb;115(2):324-333.e2.
  18. Tso, M., Lam, T. (1996) “Method of Retarding and Ameliorating Central Nervous System and Eye Damage.”
  19. Huang, et al. (2016). “A randomized, double-blind, placebo-controlled study of oral antioxidants supplement therapy in patients with dry eye syndrome.” Journal of Clinical Ophthalmology.10:813-820.
  20. Yasunori, N., et. al. (2005). “The effect of astaxanthin on retinal capillary blood flow in normal volunteers.” J. Clinc. Ther. Med. 21(5): 537-542.
  21. Nitta, T., Ogami, K., Shiratori, K. (2005). “The effects of Astaxanthin on Accommodation and Asthenopia-Dose Finding Study in Healthy Volunteers.” Clinical Medicine. 21(5):543-556.
  22. Kaplan NM. The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149:1514-20.
  23. Dr Siti K.A.T., Malaysia and WHO calls for more investment in primary health care the 21st century. WHO. 8 April 2019.
  24. Dr. Zulkefly A., Malaysia has 3.6 million diabetics. The Star, 27 March 2019.
  25. Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K, Shirahata A, Taniyama M. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obesity. 2003;11:1072-9. doi: 10.1038/oby.2003.147.
  26. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-5. doi: 10.1210/jcem.86.5.7463.
  27. Yoshida H, Yanai H, Ito K, Tomono Y, Koikeda T, Tsukahara H, Tada N. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis. 2010;209:520-23. doi: 10.1016/j.atherosclerosis.2009.10. 012.
  28. Yanai H, Ito K, Yoshida H, Tada N. Antihypertensive effects of astaxanthin. Intergrated Blood Pressure Control. 2008:1:1-3.
  29. Fassett, RG., et al. (2008). “Astaxanthin versus placebo on arterial stiffness, oxidative stress, and inflammation in renal transplant patients: a randomized, controlled trial,” BMC Nephrology. 9:17.
  30. Miyawaki, H., et al. (2008). “Effects of astaxanthin on human blood rheology,” Journal of Clinical Biochemistry Nutrition. 43(2): 9–74.
  31. Hussein G1, et al. (2006). “Antihypertensive potential and mechanism of action of astaxanthin: III. Antioxidant and histopathological effects in spontaneously hypertensive rats.” Biological and Pharmaceutical Bulletin. 29(4):684-88.
  32. Yoshida H., et al. (2010). “Administration of natural astaxanthin increases serum HDL cholesterol and adiponectin in subjects with mild hyperlipidemia,” Atherosclerosis. 209: 520–523.
  33. Awamoto, T., et al. (2000).“Inhibition of low-density lipoprotein oxidation by astaxanthin,” Journal of Atherosclerosis Thrombosis. 7(4): 216–222.
  34. Sawaki K. et al. (2004). Sports Performance Benefits from Taking Natural Astaxanthin, Characterized by Visual Acuity and Muscle Fatigue. Sports and Health Science Department, Juntendo University.
  35. Haehling SV et al. (2018). Time to Jump on the Bandwagon: Journal of Cachexia, Sarcopenia and Muscle in 2018.
  36. Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, Han JA, Yim SV, Chang K, Kwon YG, Lee SK, Kim YM. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells. 2003 Aug 31;16(1):97-105. PubMed PMID: 14503852.
  37. Gene A. Spiller, PhD, Antonella Dewell, MS, RD, Sally Chaves, RN, Zaga Rakidzich. Effect of daily use natural astaxanthin on C-reactive protein. Health Research & Studies Center, Los Altos, CA. Study Report, January, 2006.
  38. Nakagawa K et al. Br J Nutr. 2011;31:1-9 13.)(Miyawaki H et al. Journal of Clinical Therapeutics and Medicines. 2008;21:4.
  39. Aoi W et al. Biochem Biophys Res Commun. 2008; 366(4):892-897)( 7. Yamashita E. In: Anti-Aging Therapeutics Volume XII. 2010. p:345-359. ISBN 978-1-934715-05-5)( 14. Wolf AM et al. J Nutr Biochem. 2010;21(5):381-389.
  40. Guerin, M., et al. (2002). “Haematococcus astaxanthin: health and nutrition ap- 177 plications.” Presented at the 1st Congress of the International Society for Applied Phycology/9th International Congress on Applied Phycology, May 26-30, 2002, Almeria, Spain.
  41. Earnest, CP., et al. (2011). “Effect of astaxanthin on cycling time trial performance.” International Journal of Sports Medicine.
  42. Sawaki, K., et al. (2002). “Sports performance benefits from taking natural astaxanthin characterized by visual acuity and muscle fatigue improvements in humans.” Journal of Clinical Therapeutics & Medicines.18:(9)73-88.
  43. A collaboration between International Medical University (IMU) and Alzheimer’s Disease Foundation of Malaysia (ADFM): Raising Awareness of Alzheimer’s in Malaysia. 6 September 2017.
  44. Ikeda, Y., et al. (2008). “Protective effects of astaxanthin on 6-hydroxydopamin-induced apoptosis in human neuroblastoma SH-SY5Y cells.” Journal of Neurochemistry. 107(6):1730-40.
  45. Wang, HQ., et al. (2010). “Astaxanthin upregulates heme oxygenase-1 expression through ERK1/2 pathway and its protective effect against beta-amyloidinduced cytotoxicity in SH-SY5Y cells.” Brain Research. 1360:159-67.
  46. Baby, L.P., et al. (2015) Surprising Natural Treatment for Alzheimer’s Disease: Coconut Oil. International Journal of Current Multidisciplinary Studies. 1(2):74-81.
  47. Liu, X., et al. (2009). “Astaxanthin inhibits reactive oxygen species mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism.” Brain Research. 1254:18-27.
  48. Chang, CH., et al. (2010). “Astaxanthin secured apoptotic death of PC12 cells induced by beta-amyloid peptide 25-35: Its molecular action targets.” Journal of Medicinal Food. 13(3):548-556.
  49. Curek, GD., et al. (2010). “Effect of astaxanthin on hepatocellular injury following ischemia/reperfusion.” Toxicology. 267(1- 3):147-153.
  50. Lu, YP., et al. (2010). “Neuroprotective effect of astaxanthin on H(2)O(2)-induced neurotoxicity in vitro and on focal cerebral ischemia in vivo.” Brain Research. 1360:40-48.
  51. Lee, S., et al. (2003). “Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing IkB Kinase-dependent NFR-kB activation.” Molecules and Cells. 16(1):97-105.
  52. Abbas, A. A. et al. (2017). Antimicrobial Activity of Coconut Oil and its Derivatives (Lauric Acid) on Some Selected Clinical Isolates. International Journal of Medical Science and Clinical Invention. 4(8):3173-3177.
  55. Wang, X., Willen, R., Wadstrom, T. (2000). “Astaxanthin-rich algal meal and vitamin C inhibit Helicobacter pylori infection in BALB/cA mice.” Antimicrobial Agents and Chemotherapy. 44(9):2452-7.
  56. Kurashige, M., Okimasu, M., Utsumi, K. (1990). “Inhibition of oxidative injury of biological membranes by astaxanthin.” Physiol. Chem. Phys. Med. NMR 22(1):27-38
  57. Kang, J., Kim, S., Kim, H. (2001). “Effect of astaxanthin on the hepatotoxicity, lipid peroxidation and antioxidative enzymes in the liver of CCl4-treated rats.” Methods and findings in experimental and clinical pharmacology. 23(2):79-84.
  58., Astaxanthin.
  59., The Whole Body Benefits of Natural Astaxanthin.
  60. January 31, 2017.
  61. Huffington Post April 30, 2013.
  62., Astaxanthin Research.
  63. Astaxanthin.